Asosiy kontentga oʻtish
AkademIndex

Xizmatlar

ESMO Open

16 ta ish

Jurnal · ISSN 2059-7029

AkademScholarda batafsil koʻrsatkichlar

  1. PO-291 The disbalance of the basic cytokines of the immune system in patients with ovarian cancer on the background of immunotherapy

    S. Kamishov

    MaqolaOchiq kirishCancer Immunotherapy and BiomarkersESMO Open20180 iqtibos
    ABI

  2. 10P Neoadjuvant chemotherapy with bevacizumab for IIb stage cervical cancer: Is it time to rethink standard of care?

    F.M. Djuraev, A.S. Abdujapparov

    MaqolaOchiq kirishEndometrial and Cervical Cancer TreatmentsESMO Open20230 iqtibos
    ABI

  3. 19P Neoadjuvant chemotherapy followed by radical surgery vs chemoradiotherapy in patients with cervical cancer (stage IIB, FIGO 2018)

    A.S. Abdujapparov, F. Djuraev, N.O. Zaynutdinov

    MaqolaOchiq kirishEndometrial and Cervical Cancer TreatmentsESMO Open20230 iqtibos
    ABI

  4. 39P The possibility of predicting the effectiveness of treatment of soft tissue sarcomas on the basis of the properties of their immunologic microenvironment

    Н.К. Асамединов, D. Polatova, Nargiza Karimova +5

    MaqolaOchiq kirishCAR-T cell therapy researchESMO Open20240 iqtibos
    ABI

  5. 35P Beyond microsatellite testing: Tumor mutational burden, should it be routine in patients with GI cancers?

    F.M. Djuraev, A.S. Abdujapparov

    MaqolaOchiq kirishGenetic factors in colorectal cancerESMO Open20240 iqtibos
    ABI

  6. 95P The study of immune microenvironment subpopulations in soft tissue sarcomas

    E.K.Q. Azimova, D. Polatova, Nargiza Karimova +2

    MaqolaOchiq kirishCancer Immunotherapy and BiomarkersESMO Open20240 iqtibos
    ABI

  7. 111P Oncologic outcomes of the pelvic bone tumors

    A.I. Nurjabov, N.S. Kamalovich, Н.К. Асамединов +4

    MaqolaOchiq kirishEndometrial and Cervical Cancer TreatmentsESMO Open20240 iqtibos
    ABI

  8. 153P The preoperative treatment of patients with giant cell tumors of limb bones by denosumab therapy

    N.S. Kamalovich, D. Polatova, K. Abdikarimov +6

    MaqolaOchiq kirishBone Tumor Diagnosis and TreatmentsESMO Open20240 iqtibos
    ABI

  9. 68P The effectiveness of treatment of ascites due to recurrence of platinum-refractory ovarian cancer using metronomic chemotherapy

    S. Shaxanova

    MaqolaOchiq kirishOvarian cancer diagnosis and treatmentESMO Open20240 iqtibos
    ABI

  10. 30P Cemiplimab in treatment of metastatic and recurrent cervical cancer

    F.M. Djuraev, A.S. Abdujapparov

    MaqolaOchiq kirishCancer Immunotherapy and BiomarkersESMO Open20240 iqtibos
    ABI

  11. 74P The influence of genetic phenotype on prognosis of osteosarcoma

    N.S. Kamalovich, D. Polatova, K. Abdikarimov +5

    MaqolaOchiq kirishSarcoma Diagnosis and TreatmentESMO Open20240 iqtibos
    ABI

  12. 125P Possibility of using the combination everolimus/sorafenib combination of medications in the treatment of children and adolescents with refractory osteosarcoma and Ewing sarcoma

    Н.К. Асамединов, K. Abdikarimov, D.R. Rasulbek Rakhimberdiyevich +3

    MaqolaOchiq kirishSarcoma Diagnosis and TreatmentESMO Open20250 iqtibos
    ABI

  13. 123P The treatment by denosumab of patients with giant cell tumors of bones

    N.S. Kamalovich, D. Polatova, K. Abdikarimov +5

    MaqolaOchiq kirishBone Tumor Diagnosis and TreatmentsESMO Open20250 iqtibos
    ABI

  14. 137P Treatment of inoperable or locally advanced giant cell tumor of bone

    A.I. Nurjabov, K. Abdikarimov, D. Polatova +5

    MaqolaOchiq kirishBone Tumor Diagnosis and TreatmentsESMO Open20250 iqtibos
    ABI

  15. 75eP Mutational spectrum of KRAS, TP53, BRAF, ERBB2, and POLE in GI malignancies across diverse populations

    Nikhil Ghadyalpatil, Umut Dişel, O. Zilola +15

    MaqolaOchiq kirishChromatin Remodeling and CancerESMO Open20250 iqtibos
    ABI

  16. 63P Combination of pembrolizumab lenvatinib in treatment of advanced hepatocellular carcinoma

    Z. Alisher, F.M. Djuraev

    MaqolaOchiq kirishHepatocellular Carcinoma Treatment and PrognosisESMO Open20260 iqtibos
    ABI